Cited by 152Drug Transport and Resistance MechanismsCannabis and Cannabinoid ResearchPharmacogenetics and Drug Metabolism

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids

Open access

Holland, M L, Lau, D T T, Allen, J D, Arnold, J C·2007·British Journal of Pharmacology

DOI 10.1038/sj.bjp.0707467PMC PMC2190019

Open this paper in CoChat — free account Open PDF

Abstract

Background and purpose: Cannabinoids are used therapeutically for the palliation of the adverse side effects associated with cancer chemotherapy. However, cannabinoids also inhibit both the activity and expression of the multidrug transporter, P‐glycoprotein in vitro . Here we address the interaction of cannabinol (CBN), cannabidiol (CBD) and Δ 9 ‐tetrahydrocannabinol (THC) with the related multidrug transporter, ABCG2. Experimental approach: Cannabinoid inhibition of Abcg2/ABCG2 was assessed using flow cytometric analysis of substrate accumulation and ATPase activity assays. The cytotoxicity and chemosensitization by cannabinoids was determined with cell viability assays. Expression of cannabinoid and vanilloid receptors was assessed using reverse transcriptase polymerase chain reaction, and cannabinoid modulation of ABCG2 expression was examined using immunoblotting. Key results: CBN, CBD and THC increased the intracellular accumulation of the Abcg2/ABCG2 substrate, mitoxantrone, in an over‐expressing cell line. The THC metabolite, (−)‐11‐nor‐9‐carboxy‐Δ 9 ‐THC was much less potent. The plant cannabinoids inhibited both basal and substrate stimulated ATPase activity of human ABCG2. Cannabinoid cytotoxicity occurred in the absence of known cannabinoid cell surface receptors, and only at concentrations higher than those required for Abcg2/ABCG2 inhibition. Sub‐toxic concentrations of the cannabinoids resensitized the overexpressing cell line to the cytotoxic effect of Abcg2/ABCG2 substrates, mitoxantrone and topotecan. This occurred in the absence of any effect on ABCG2 expression. Conclusions and implications: Cannabinoids are novel Abcg2/ABCG2 inhibitors, reversing the Abcg2‐mediated multidrug‐resistant phenotype in vitro . This finding may have implications for the co‐administration of cannabinoids with pharmaceuticals that are ABCG2 substrates. British Journal of Pharmacology (2007) 152 , 815–824; doi: 10.1038/sj.bjp.0707467 ; published online 1 October 2007

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0707467

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. W. T. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,317
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T. A., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,372
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., & Schellens, J. H. M. (2001) · PubMed · Cited by 1,130
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1188 · Cited by 721
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Allen, J. D., van Loevezijn, A., Rademaker-Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J. H. M., Koomen, G., & Schinkel, A. H. (2002) · PubMed · Cited by 690
Self-citation
Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
Jonker, J. W. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1651 · Cited by 639
Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase.
Sarkadi, B., Price, E. M., Boucher, R. C., Germann, U. A., & Scarborough, G. A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42909-2 · Cited by 633
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review
Tramèr, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001) · BMJ · doi:10.1136/bmj.323.7303.16 · Cited by 610

Flagged first, then by citations

Show all 38 references

Sorted by citations

Items 101–152 of 152

In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters
Etchart, M. G., Anderson, L. L., Ametovski, A., Jones, P. M., George, A. M., Banister, S. D., & Arnold, J. C. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174836 · Cited by 7
Self-citation
Overview of the Endocannabinoid System and Endocannabinoidome
Davis, M. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-89918-9_1 · Cited by 6
Molecular Targets for Cannabinoids in Natural Killer Cells: Do They Modulate the Antitumor Activity?
Olivas-Aguirre, M., Gutiérrez-Iñiguez, C., Pottosin, I. I., & Dobrovinskaya, O. R. (2024) · Receptors · doi:10.3390/receptors3020007 · Cited by 6
Combinatorial approach of cannabidiol and active‐targeted‐mediated photodynamic therapy in malignant melanoma treatment
Nkune, N. W., & Abrahamse, H. (2024) · Journal of Biophotonics · doi:10.1002/jbio.202400191 · Cited by 6
Medical potential of cannabis
Zielonka, D. M., Kiraga, Ł., & Kozlowski, R. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818782-1.00012-2 · Cited by 6
Effects of concomitant use of THC and irinotecan on tumour growth and biochemical markers in a syngeneic mouse model of colon cancer
Žunec, S., Karačonji, I. B., Čatalinac, M., Jurič, A., Katić, A., Kozina, G., Micek, V., Neuberg, M., & Vrdoljak, A. L. (2023) · Archives of Industrial Hygiene and Toxicology · doi:10.2478/aiht-2023-74-3765 · Cited by 5
Pediatric Dosing Considerations for Medical Cannabis
Alcorn, J., Vuong, S., Wu, F. P., Seifert, B. W., & Lyon, A. W. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85399 · Cited by 5
Cannabinoids: Chemistry and Medicine
Appendino, G., & Taglialatela‐Scafati, O. (2013) · Springer eBooks · doi:10.1007/978-3-642-22144-6_147 · Cited by 5
Human Data on Pharmacokinetic Interactions of Cannabinoids: A Narrative Review
Maldonado, C., Peyraube, R., Fagiolino, P. L., Oricchio, F., Cuñetti, L., & Vázquez, M. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128288510240113170116 · Cited by 4
Molecular targets of cannabinoids and their derivatives in epilepsy – a review with focus on CBD
Marciniak, S., Wasyluk, W., & Wojtak, A. (2025) · Acta Biochimica Polonica · doi:10.3389/abp.2025.15251 · Cited by 3
Immunomodulatory and anticancer effects of phytochemicals: A comprehensive analysis
Eltokhy, M. A., Curcic, M., Modaresahmadi, S., Gaikwad, S. R., La-Beck, N. M., & Srivastava, S. K. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100134 · Cited by 3
Medical marijuana in cancer: harmful or harm reduction?
Thielmann, A., & Daeninck, P. J. (2013) · Clinical Practice · doi:10.2217/cpr.13.15 · Cited by 3
Inhibition of ATP-Binding Cassette Transporters by Chinese Herbs and Phytochemicals
Efferth, T. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0442-2_7 · Cited by 3
The Effects of Drugs of Abuse on ABC Transporters
Hussein, N. A., Muskiewicz, D. E., Terrero, D., Malla, S., Hall, F. S., & Tiwari, A. K. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_184 · Cited by 3
Pharmacogenetics in Epilepsy and Refractory Epilepsy
Czornyj, L. A., Auzmendi, J., & Lazarowski, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-36526-3_10 · Cited by 4
Adverse events associated with the use of cannabis-based products in people living with cancer: A scoping review protocol
Cheah, I., Gelissen, I. C., Hunter, J., & Harnett, J. (2023) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2023.102279 · Cited by 2
High Doses of Δ9-Tetrahydrocannabinol Might Impair Irinotecan Chemotherapy: A Review of Potentially Harmful Interactions
Kopjar, N., Fuchs, N., Karačonji, I. B., Žunec, S., Katić, A., Kozina, G., & Vrdoljak, A. L. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00954-y · Cited by 2
Cannabinoid-Based Medicine: Pharmacology and Drug Interactions
Davis, M. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-89918-9_2 · Cited by 2
Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus
Gómez, C. T., Fernandez, F., Jara, A., Borda, N., Moscovicz, F., Huamán, Y. Y., Robles, R. J. C., Pacheco‐Otálora, L. F., Lazarowski, A., & Auzmendi, J. (2026) · Brain Sciences · doi:10.3390/brainsci16080851 · Cited by 1
Phytocannabinoid-drug interactions: pharmacokinetic and pharmacodynamic mechanisms, clinical relevance and toxicological considerations
Gomes, D. A., Eufrazio, W. V., Ribeiro, M. S., Júnior, L. R. D. N., Rigo, F. K., Amaral, P. D. A., Campanale, A., Inserra, A., & de Bitencourt, R. M. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1952599 · Cited by 1
Cannabis and Cancer
Ross, I. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-35155-6_10 · Cited by 1
Cannabidiol safety
Charrette, A., Akingbasote, J. A., Guthrie, N., & Hilmas, C. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821038-3.00039-2 · Cited by 1
Implications and quantifications of marijuana use regarding neonatal outcomes
Yu, Z., Fitzgerald, M., Li, R., Amos, J., & Luo, L. (2022) · Phytomedicine Plus · doi:10.1016/j.phyplu.2022.100304 · Cited by 1
Emerging Role of Cannabinoid System Modulators in Treatment of Cancer
Singh, S., Pattanaik, S., Mavuduru, R. S., & Singh, S. K. (2022) · Springer eBooks · doi:10.1007/978-981-16-9232-1_12 · Cited by 1
Determining the Cytotoxic Properties and Mechanisms Against Drug Resistance of an Aqueous Extract of Fagonia indica on Colon Cancer CellsPreprint
Lewis, A., Shelton, C. D., Wang, W., Kannappan, V., Carmichael, A. R., Rothnie, A. J., & Brown, J. E. P. (2021) · Preprints.org · doi:10.20944/preprints202103.0168.v1 · Cited by 1
Development and application of a LC-MS/MS method for the analysis of plasma bioavailabilities of different cannabinoids after the administration of "Cannabis sativa L." extracts and MarinolTM
Grauwiler, S. B. (2008) · edoc (University of Basel) · doi:10.5451/unibas-004544748
Validation of novel therapeutic target molecules in pediatric sarcomas
Oesch, S. (2009) · Zurich Open Repository and Archive (University of Zurich) · doi:10.3929/ethz-a-005836696
Pharmakologische Grundlagen: Das Schicksal psychoaktiver Substanzen im menschlichen Körper
Hohmann, N. (2017) · Springer eBooks · doi:10.1007/978-3-642-55125-3_2
Cannabinoids: Chemistry and Medicine 112
Appendino, G., & Taglialatela‐Scafati, O. (2013)
[Role of breast cancer resistance protein in drug disposition].
Wu, X., Li, S., Jia, Y., & Li, Y. (2016) · PubMed
The Effects of Drugs of Abuse on ABC Transporters
Hussein, N. A., Muskiewicz, D. E., Terrero, D., Malla, S., Hall, F. S., & Tiwari, A. K. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_184-1
Peer Review #2 of "ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice (v0.2)"
(2016) · PeerJ · doi:10.7287/peerj.2081v0.2/reviews/2
Peer Review #1 of "ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice (v0.1)"
(2016) · PeerJ · doi:10.7287/peerj.2081v0.1/reviews/1
Peer Review #1 of "ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice (v0.2)"
(2016) · PeerJ · doi:10.7287/peerj.2081v0.2/reviews/1
Peer Review #1 of "Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines (v0.1)"
(2013) · PeerJ · doi:10.7287/peerj.153v0.1/reviews/1
Peer Review #2 of "Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines (v0.1)"
(2013) · PeerJ · doi:10.7287/peerj.153v0.1/reviews/2
Peer Review #3 of "Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines (v0.1)"
(2013) · PeerJ · doi:10.7287/peerj.153v0.1/reviews/3
Peer Review #3 of "ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice (v0.2)"
(2016) · PeerJ · doi:10.7287/peerj.2081v0.2/reviews/3
Pharmakologische Grundlagen: Das Schicksal psychoaktiver Substanzen im menschlichen Körper
Hohmann, N. (2016) · Springer eBooks · doi:10.1007/978-3-642-55214-4_2-1
Peer Review #2 of "ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice (v0.1)"
(2016) · PeerJ · doi:10.7287/peerj.2081v0.1/reviews/2
Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and Astrocytes under Hypoxic Conditions
Auzmendi, J., Palestro, P. H., Blachman, A., Gavernet, L., Merelli, A., Talevi, A., Calabrese, G. C., Ramos, A. J., & Lazarowski, A. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pans.1.2020.22
Peer Review #3 of "ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice (v0.1)"
(2016) · PeerJ · doi:10.7287/peerj.2081v0.1/reviews/3
Targeting carbohydrate metabolism in colorectal cancer - synergy between DNA-damaging agents, cannabinoids, and intermittent serum starvation
Cherkasova, V., Kovalchuk, O., & Kovalchuk, I. (2024) · Oncoscience · doi:10.18632/oncoscience.611
The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro
Alexander, S. P. H. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_605
The Pharmacokinetic and Pharmacodynamic Drug-drug Interaction Potential of Cannabidiol
Keller, G. A., & Aimar, J. A. (2025) · Drug Metabolism and Bioanalysis · doi:10.2174/0118723128411684251029100517
Chapter 7: Drug Interactions and Pharmacogenetic Considerations
(2025) · The American Pharmacists Association eBooks · doi:10.21019/9780914768081.ch7
Cannabidiol enhances tamoxifen efficacy via CREB-mediated suppression of ERα signaling in ER-positive breast cancer cells
Kim, B. G., Kim, O., Lee, D.-Y., Kim, B. R., Kim, D. Y., Namgung, Y., Bong, J. W., Kang, S., Lee, S. I., & Oh, S. C. (2026) · Cell & Bioscience · doi:10.1186/s13578-026-01588-x
A Comparative Analysis of the Action Mechanisms of Cannabidiol, Cannabigerol, and Cannabinol in Human Cholangiocarcinoma Cell Lines
Laprom, S., Shuntawiwat, B., Rattanacheeworn, P., Jaisin, Y., Choowongkomon, K., & Samatiwat, P. (2026) · Molecules · doi:10.3390/molecules31142446
GPR55 and PINK1 as emerging therapeutic targets in Glioma: insights into their modulation by phytochemicals and plant extracts
Smith, A. D. T., Perez, J. C. M., Loaiza, J. C. M., & Arboleda, G. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1760169
Cannabinoids in hematologic malignancies: mechanisms and therapeutic potential for overcoming drug resistance
Li, S., Jian, X., Tang, Y., Wang, Z., Min, T., Yu, L., Jiang, B., & He, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1921501
BindingDB Entry 50015583: Phytocannabinoid Pharmacology: Medicinal Properties of
BindingDB (2023) · UC San Diego · doi:10.7270/q2057kwp
BindingDB Entry 50016463: Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
BindingDB (2023) · UC San Diego · doi:10.7270/q2pz5dt3

Authors: Holland, M. L., Lau, D. T. T., Allen, J. D., & Arnold, J. C.
Affiliations: The University of Sydney (AU)
Centenary Institute (AU)
Corresponding author: Arnold, J C
ORCID: Holland, M L
Arnold, J C
Venue: British Journal of Pharmacology
Publisher: Wiley
Published: 2007-11
Volume: 152
Issue: 5
Pages: 815-824
ISSN: 0007-1188 (ISSN-L)
1476-5381
DOI: 10.1038/sj.bjp.0707467
PMC: PMC2190019
OpenAlex: W1571533074
Cited by: 150
References: 38
Citations by year: 2026: 7 · 2025: 7 · 2024: 8 · 2023: 14 · 2022: 14 · 2021: 11 · 2020: 13 · 2019: 11 · 2018: 9 · 2017: 5 · 2016: 14 · 2015: 6 · 2014: 3 · 2013: 10 · 2012: 6
FWCI: 1.01
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 455 d)
Locations: British Journal of Pharmacology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Medical Research Council
National Health and Medical Research Council
Topics: Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords: ABCG2, multidrug transporter, cannabinol, cannabidiol, delta-9-tetrahydrocannabinol, multidrug resistance, chemosensitization, mitoxantrone, topotecan, cannabinoid receptors, vanilloid receptor, drug-drug interactions
MeSH terms: ATP Binding Cassette Transporter, Subfamily G, Member 2, Adenosine Triphosphatases, Animals, Cannabinoids, Cell Line, Cell Survival, Dose-Response Relationship, Drug, Flow Cytometry, Humans, Mitoxantrone, Neoplasm Proteins, Plant Extracts, Sulfasalazine, Dronabinol, Immunoblotting, ATP-Binding Cassette Transporters, Topotecan, Inhibitory Concentration 50, Reverse Transcriptase Polymerase Chain Reaction, Receptor, Cannabinoid, CB1, Cell Line, Tumor, TRPV Cation Channels, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks